
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is a rapidly growing biotechnology company, with strong partnerships and collaborations in place to drive revenue growth. While the recent sale of convertible senior notes may be a cause for concern, the company has a large cash position and is well-positioned to expand into new diseases and continue to go public. Overall, the company has a positive outlook for future growth and is a highly rated Buy by analysts.
Bears say
Tempus AI is facing several fundamental challenges that may hinder its growth and profitability. These include potential risks such as lower-than-projected sales growth, inability to develop and secure regulatory approval of new products, and difficulties in acquiring and maintaining partnerships with biopharmaceutical companies. These challenges could result in weaker than expected revenue growth and margin expansion, increase the company's cash burn, and require additional capital raising. Additionally, competition in the decentralized market and the impact of new legislation on laboratory developed tests may impact the company's competitiveness and profitability. Overall, these risks present a negative outlook for Tempus AI's stock.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares